Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Other Non-Current Assets of $26.0 million for Q1 2026, down 33.33% year-over-year from $39.0 million in Q1 2025, and down 3.7% quarter-over-quarter from $27.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $26.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 33.33% year-over-year to $26.0 million; the TTM figure through Mar 2026 stood at $26.0 million (down 33.33% YoY), while the FY2025 annual figure was $27.0 million, down 30.77% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $26.0 million, down from $27.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $44.0 million in Q2 2025, with the low at $26.0 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $37.0 million (2022), against an average of $34.5 million.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets tumbled 64.15% in 2022, then climbed 8.33% in 2024.
- Indivior Pharmaceuticals' Other Non-Current Assets stood at $38.0 million in 2022, then decreased by 5.26% to $36.0 million in 2023, then climbed by 8.33% to $39.0 million in 2024, then tumbled by 30.77% to $27.0 million in 2025, then declined by 3.7% to $26.0 million in 2026.
- Business Quant data shows INDV's Other Non-Current Assets at $26.0 million in Q1 2026, $27.0 million in Q4 2025, and $27.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 13.00 Mn |
| 10 | Indivior Pharmaceuticals | 4.51 Bn | 4.29 Bn | 294.00 Mn | 24.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.00 Mn |
| Mar 31, 2026 | 26.00 Mn |
| Dec 31, 2025 | 27.00 Mn |
| Sep 30, 2025 | 27.00 Mn |
| Jun 30, 2025 | 44.00 Mn |
| Mar 31, 2025 | 39.00 Mn |
| Dec 31, 2024 | 39.00 Mn |
| Dec 31, 2023 | 36.00 Mn |
| Dec 31, 2022 | 38.00 Mn |
| Dec 31, 2021 | 106.00 Mn |